In tablet wet granulation, sodium carboxymethylcellulose is incorporated either as dry intragranular powder at 1–4% w/w of the dry blend or as a pre-hydrated aqueous binder solution containing 2–5% w/w solids. Low- and medium-viscosity pharma grades with nominal 2% w/w aqueous viscosity of 25–400 mPa·s at 25 °C on a Brookfield LV rotational viscometer are preferred because higher viscosity grades produce non-pumpable fluids and require extended wet massing. On a high-shear granulator with impeller tip speed 5–8 m/s and chopper speed 1,500–3,000 rpm, binder addition is performed at 5–15 g/min per kg dry powder; final granulation endpoint is identified by impeller torque increase of 10–20% relative to dry mixing. Over-granulation is observed when binder level exceeds 6% w/w of the dry blend or wet massing continues beyond 5 min after visual endpoint, yielding granules with mass median particle size above 850 µm and fines fraction below 10% passing 75 µm. Dried granules are milled through a 0.8–1.2 mm screen and compressed on a rotary tablet press at 8–15 kN compression force using B or D tooling; ejection force is monitored to avoid tooling wear and tablet picking. The finished immediate-release tablet is tested for content uniformity under USP <905>, disintegration under USP <701>, dissolution under USP <711>, and loss on drying under USP <731>. Because sodium CMC is hygroscopic, granules should be compressed at room humidity below 60% RH to prevent picking and sticking on punch faces. Degree of substitution in pharma grades typically falls within 0.60–0.85; the exact value influences hydration rate, gel clarity, and the risk of polymer-rich agglomerates in the granule.

What Limits Capsule-Fill Disintegration When CMC Sodium Is Used as an Intragranular Binder?

Sodium carboxymethylcellulose in capsule fill granulations is generally added intragranularly at 1–3% w/w of the dry fill weight; the selected grade usually has nominal 2% w/w aqueous viscosity of 25–100 mPa·s at 25 °C to avoid long hydration times. Dry mixing is conducted in a bin blender at 20–35 rpm for 15 min, followed by wet granulation with purified water or a hydroalcoholic mixture and fluid-bed drying at 50–60 °C inlet air to a loss-on-drying limit below 2.0% w/w. The dried granulate is milled through a 0.8 mm screen and filled into hard gelatin or HPMC capsules using dosator or tamping-pin machines; fill weight variation is controlled to ±5% for target weights below 300 mg and ±3% for larger fills. Dissolution behaviour is impacted by the gel-forming nature of CMC sodium: when granule tap density exceeds 0.6 g/mL and binder concentration exceeds 3% w/w, disintegration time under USP <701> can extend beyond 15 min in purified water at 37 °C with discs, and Q-values at 30 min under USP <711> Apparatus II at 50 rpm may fall below 80% label claim. Croscarmellose sodium at 1–2% w/w may be included as a disintegrant; croscarmellose sodium is chemically cross-linked carboxymethylcellulose and functions by wicking, while non-cross-linked CMC sodium functions primarily as binder and gel former. The chemically related but functionally divergent behaviour of these two cellulose derivatives must be considered before substitution in a registered formulation.

In oral suspension manufacturing, medium- and high-viscosity sodium carboxymethylcellulose grades are hydrated to create a structured aqueous vehicle that retards particulate sedimentation and ensures uniform dosing after shaking. The suspension vehicle is typically prepared at 0.3–1.5% w/v CMC sodium, depending on the nominal 2% w/w viscosity grade of 400–4,000 mPa·s at 25 °C; the polymer is dispersed under high shear in cold purified water using a rotor-stator homogenizer at 3,000–6,000 rpm for 20–30 min and then allowed to hydrate without shear for 60 min. High-shear dispersion minimizes partially hydrated gel agglomerates, known as fish eyes, which can block transfer lines and cause viscosity drift. The finished suspension is adjusted to pH 5.0–7.5, and sodium benzoate at 0.1–0.2% w/v or potassium sorbate at 0.1% w/v may be included as preservative if chemical compatibility with the anionic polymer is confirmed by assay. A production-scale failure mode in suspension lines is air entrainment in high-viscosity vehicles; vacuum deaeration at −0.6 to −0.8 bar for 30 min is often required to reach a finished density within 1.00–1.05 g/mL. The finished oral suspension is evaluated for viscosity on a Brookfield rotational viscometer at 25 °C, sedimentation volume after 24 h, and redispersibility; microbiological quality is tested under USP <1111> or the relevant Ph. Eur. acceptance criteria. Strongly cationic drug substances at high concentration can reduce hydrated viscosity through ionic interaction; published data for specific cationic API–CMC combinations are limited, and laboratory screening at polymer concentrations of 0.1%, 0.5%, and 1.0% w/v is necessary before defining the commercial formula.

When a CMC Vehicle Is Terminally Sterilized for Injectable Depot Suspensions

Sodium carboxymethylcellulose serves as a suspending and viscosity-modifying vehicle in sterile injectable suspensions intended for intramuscular or subcutaneous depot administration. Typical concentrations for injectable vehicles range from 0.1–0.5% w/v, using low- or medium-viscosity grades of 50–400 mPa·s nominal 2% w/w viscosity to maintain syringeability through 21G–23G needles. The vehicle is prepared in Water for Injection at 20–30 °C, and the active pharmaceutical ingredient is incorporated as a sterile-micronized or aseptically milled powder. Because sodium CMC solutions at concentrations above 0.5% w/v typically cannot be sterile-filtered through 0.22 µm membrane due to high viscosity and polymer chain entanglement, terminal steam sterilization at 121 °C for 15 min is commonly selected. Steam sterilization produces measurable chain scission; post-autoclave viscosity may be lower than pre-autoclave by 10–40% depending on initial molecular weight, degree of substitution, and oxygen residuals, and published data for a specific CMC configuration should be verified through a vial-scale heat-stability study before the terminal cycle is locked. The filled vials are Type I borosilicate glass with elastomeric closures, and the finished product is tested for sterility under USP <71>, bacterial endotoxins under USP <85>, particulate matter under USP <788>, and viscosity by a pharmacopoeial rotational viscometer method. Syringeability is controlled by measuring glide force through 21G or 23G needles; the acceptance limit is product-specific rather than universal. Injectable CMC vehicles are not normally used for intravenous administration of small-molecule solutions; their application is restricted to depot suspensions where a subcutaneous or intramuscular depot is clinically required and defined in a registered marketing authorization.

Direct Compression Dry Binder and Feed-Frame Rheology Constraints

For direct compression, unmodified sodium carboxymethylcellulose is employed only in specialized formulations because non-cross-linked pharma-grade powder exhibits angular particle morphology, hygroscopicity, and poor flow. Low-viscosity grades with nominal 2% w/w viscosity of 10–50 mPa·s at 25 °C are added at 5–15% w/w to a directly compressible filler such as spray-dried lactose or microcrystalline cellulose; the resulting blend typically shows a Carr index above 25 and a Hausner ratio above 1.30, indicating passable to poor flow that requires forced feed-frame assist on high-speed rotary presses. Powder flow classification is determined under USP <1174> or the corresponding Ph. Eur. chapter. The feed frame speed is maintained at 20–40 rpm and the tablet press turret speed is reduced to 20–40 rpm to avoid weight variation outside ±3% for a target tablet weight of 200 mg. Tablets compressed at 10–18 kN may reach hardness values of 5–8 kp; however, this firmness can decline as ambient humidity exceeds 60% RH because absorbed water plasticizes the CMC domains. The direct compression approach with unmodified CMC sodium is generally restricted to low-dose immediate-release tablets where rapid dissolution is not rate-limiting. When robust direct compression is required, co-processed CMC-based excipients with added flow aids and disintegrants are preferred; published comparative compaction data for plain CMC sodium in direct compression remain limited, so formulation decisions should be based on instrumented tablet press data for the specific grade rather than extrapolation from other cellulose ethers.

When dry granules for reconstitution are filled into stick-pack or sachet formats, the dispersion behaviour of sodium carboxymethylcellulose determines the time to full homogenization after the patient adds water. In this application, low- or medium-viscosity CMC sodium is granulated with sucrose, dextrose, or mannitol at 2–10% w/w of the dry fill weight; the polymer functions both as a granule binder during wet massing and as a post-reconstitution suspending agent. The granulation is prepared in a fluid-bed granulator with inlet air temperature 50–70 °C and spray rate 10–20 g/min/kg; agglomeration is terminated when the moisture content reaches 3–5% w/w, after which the granules are dried to a loss-on-drying limit below 1.5% w/w and sieved through 1.0 mm. Finished granules are filled into low-moisture barrier sachets at fill weights of 1–5 g, with fill weight variation limits of ±5% for weights at or below 2 g and ±3% for larger weights. The reconstituted suspension is prepared by pouring the sachet content into 50–100 mL potable water at 20–25 °C; complete dispersion should occur within 30–60 s with gentle stirring. A common production issue is inter-granule caking during storage when moisture ingress exceeds 0.5% w/w; therefore, sachet seal integrity is tested by dye penetration and moisture content by Karl Fischer or loss on drying. The reconstituted product is checked for viscosity, pH, and sedimentation ratio; microbial quality should comply with the relevant non-sterile acceptance criteria in USP <1111> or Ph. Eur. 5.1.4. Because CMC sodium granules can form lumps upon contact with water if the polymer is not intimately mixed with highly soluble diluents, direct dry mixing alone is not recommended for sachet formulations intended for rapid reconstitution.

High-Viscosity CMC Forms a Release-Retarding Gel in Extended-Release Tablets

High-viscosity sodium carboxymethylcellulose grades with nominal 2% w/w aqueous viscosity of 1,500–5,000 mPa·s at 25 °C are used as hydrophilic matrix formers in extended-release tablets at 10–30% w/w of the tablet core. The matrix is prepared either by wet granulation or by direct compression; wet granulation with a low-viscosity CMC grade as binder followed by dry blending with a high-viscosity matrix grade is sometimes used to avoid over-wetting. Direct compression of high-viscosity CMC sodium is limited by poor flow and requires a separately added glidant such as colloidal silicon dioxide at 0.5–1.0% w/w. Tablet hardness is typically maintained at 8–14 kp; porosity below 10% may delay gel layer formation and accelerate release, while porosity above 20% may allow hydrodynamic erosion rather than diffusion-controlled release. Dissolution testing is conducted under USP <711> Apparatus I or II with sinkers, using media such as 0.1 N HCl for the first 2 h followed by pH 6.8 phosphate buffer; sampled time points are set by the target release profile, commonly 1, 2, 4, 8, 12, and 24 h. CMC sodium hydrates rapidly and forms a gel layer whose thickness and viscosity depend on the grade, concentration, and ionic strength of the dissolution medium; in high-ionic-strength media, gel swelling can be suppressed and release rate may increase. The key operational constraint is that high-viscosity CMC sodium can cause tablet-to-tablet variability in gel layer formation if the granulation contains fines below 75 µm exceeding 20%; therefore, the milled granulate is delumped rather than intensively milled. The extended-release formulation must be validated under ICH stability conditions and dissolution acceptance criteria defined by the product-specific registered specification.